Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial.

Philip S HelliwellAtul DeodharAlice B GottliebWolf-Henning BoehnckeXie L XuStephen XuYuhua WangElizabeth C HsiaDafna D GladmanChristopher T Ritchlin

Published in: Arthritis care & research (2020)

Guselkumab demonstrated efficacy in achieving low disease activity/remission based on all PsA composite indices assessed. Composite index use in PsA trials and the clinic requires careful consideration to optimize feasibility and instrument performance.

Keyphrases

disease activity
systemic lupus erythematosus
rheumatoid arthritis
rheumatoid arthritis patients
prostate cancer
ankylosing spondylitis
juvenile idiopathic arthritis
radical prostatectomy
primary care
patient reported outcomes
open label
clinical trial
randomized controlled trial